Summary
This 2021 European Heart Rhythm Association practical guide provides evidence-based recommendations for the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, addressing complex clinical scenarios including concurrent coronary artery disease, acute stroke whilst anticoagulated, cardioversion procedures, and management in very elderly and frail populations. The guidance aims to standardise clinical practice and support evidence-based decision-making across European healthcare systems.
Regional applicability
This European guideline is directly applicable to United Kingdom clinical practice and aligns with NICE and other UK cardiovascular guidance frameworks. The recommendations reflect contemporary evidence and can inform UK atrial fibrillation management protocols, though local implementation may vary by NHS trust.
Key measures
Clinical recommendations and evidence-based guidance for NOAC management in atrial fibrillation across specified patient populations and scenarios.
Outcomes reported
The guide synthesises evidence and provides clinical recommendations for NOAC use in atrial fibrillation patients across multiple clinical scenarios, including comorbidities, acute events, and special populations.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.